Chimerix announces offering of 6.2M shares of common stock Morgan Stanley and J.P. Morgan Securities are acting as joint book-running managers for the offering and Cowen and Company is acting as co-lead manager for the offering.
Keryx initiated with a Sell, $1.50 price target at Citi Citi analyst Yigal Nochomovitz started shares of Keryx Biopharmaceuticals (KERX) with a Sell rating and $1.50 price target. The stock closed yesterday up 18c to $6.03. Nochomovitz expects the Auryxia launch and long-term sales trends to "materially underperform" consensus expectations. Auryxia is a phosphate binder used for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Nochomovitz estimates Auryxia has peak U.S. sales potential of $57M, well below the consensus estimate of $485M. He named Chimerix (CMRX) his top pick in the small- and mid-cap biotech space. The analyst initiated the name this morning with a Buy rating and $80 price target.
Chimerix initiated with a Buy at Citi Citi analyst Yigal Nochomovitz started shares of Chimerix with a Buy rating and $80 price target. The analyst has "high conviction" that the company's brincidofovir will "transform" the lives of transplant patients and the standard of care in multiple transplant settings. Nochomovitz also calls a takeout thesis "not outrageous." Chimerix is the analyst's top pick in the small- and mid-cap biotech space.